



Obesity rates are soaring worldwide, presenting an escalating healthcare burden with huge socioeconomic cost. Research carried out by scientists at the University of Sussex and Vernalis Pharmaceuticals, on the role of the serotonin 2C receptor in modulating appetite, provided the scientific rationale for developing a new generation of anti-obesity drugs. As a result, lorcaserin, the first in its class of new serotonin 2C receptor agonists, was launched in the US in June 2013.



